Core Viewpoint - The article discusses a significant breakthrough in diabetes cell therapy, focusing on the challenge of maintaining the long-term survival and functionality of transplanted pancreatic β cells in the diabetic microenvironment, which has been a major barrier to clinical application and large-scale promotion of such therapies [2][8]. Group 1: Research Findings - The study published by the team from Tongji University reveals that zinc accumulation during diabetes progression leads to the loss of β cell identity, which is a critical mechanism in the pathogenesis of diabetes [3][5]. - The research identifies the transporter protein ZnT8 as a crucial target for diabetes prevention and treatment, as it mediates the abnormal accumulation of zinc ions in β cells [5][6]. Group 2: Innovative Approaches - The research team proposes a novel technology pathway called "resilient pancreatic organoids," which focuses on enhancing the stability and survival of pancreatic organoids under metabolic stress, addressing the long-term efficacy issues in diabetes cell therapy [6][8]. - By targeting the specific zinc transporter ZnT8, the team effectively inhibits the pathological accumulation of zinc ions in β cells, thereby protecting their identity and improving their therapeutic efficacy in diabetic conditions [6][10]. Group 3: Clinical Implications - This study represents a structural adjustment in the paradigm of diabetes cell therapy, emphasizing the need for long-term maintenance of β cell stability rather than viewing them as merely consumable functional units [8]. - The advancements made by the research team are aimed at accelerating the clinical translation of resilient pancreatic organoid technology, which has the potential to redefine diabetes treatment and benefit millions of patients globally [10].

Core Viewpoint - The research on pluripotent stem cell-derived islets (PSC-islets) shows promising potential for treating diabetes by restoring blood glucose control through the transplantation of functional insulin-producing β cells [2][4]. Group 1: Research Findings - A study published in September 2024 demonstrated successful treatment of a type 1 diabetes patient using chemically reprogrammed pluripotent stem cell-derived islets (CiPSC-islets), resulting in the patient no longer needing external insulin therapy after one year [2]. - The research published in August 2025 established a method to generate islets with complete endocrine cell types from human pluripotent stem cells (iPSCs), which effectively respond to blood glucose changes and provide hypoglycemia protection in diabetic mouse models [3][4]. - The newly constructed PSC-islets contain all five endocrine cell types (α, β, δ, ε, and γ), showcasing a robust protective effect against hypoglycemia, with only 3% of measurements falling below 54 mg/dL compared to 59% in the control group [4][10]. Group 2: Implications for Diabetes Treatment - The study highlights a strategy for controlling the relative abundance of endocrine subtypes in PSC-islets, laying the groundwork for calibrating blood glucose homeostasis and providing clear hypoglycemia protection post-transplantation [6]. - The engineered islet cell composition replicates the dual blood glucose regulation function of natural islets, which is crucial for achieving precise blood glucose control and minimizing hypoglycemia risks [8]. - This advancement offers further safety assurance for the clinical translation of stem cell-derived islets, potentially accelerating the clinical application of diabetes cell therapies [8].